Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer

NCT04733027 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT04733027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04733027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer
Lead sponsor
Institut Curie
Phase
Phase 1
Overall status
Completed
Start date
May 18, 2021
Completion date
June 11, 2026
Enrollment
77 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumor cancer